Transient Ischemic Attack Market Share

Transient Ischemic Attack Market Overview

Transient Ischemic Attack Market Size was valued at USD 0.09 Billion in 2023. The Global Transient Ischemic Attack industry is projected to grow from USD 0.12 Billion in 2024 to USD 0.29 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.24% during the forecast period (2024 - 2032).

Transient ischemic stroke is also known as a mini-stroke. It leads to temporary blockage of blood flow to the brain. As it does not cause permanent damage, it is often ignored. The market is mainly driven by factors such as the rising prevalence of ischemia stroke cases, growing geriatric population, and increasing healthcare expenditure. However, the high cost of surgical procedures for the treatment of ischemic is likely to hinder the market growth.

Transient Ischemic Attack Market Dynamics

The transient ischemic attack market is expected to exhibit exponential growth during the forecast period which is driven by all-rounder characteristics of the transient ischemic attack, increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, and increase in the treatment of chronic diseases for the elderly population. It has been identified as one of the fastest emerging industries owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an excess of public companies. 

As per the survey carried out by American Heart Association Report 2015, more than 17.9 million deaths were recorded in the US due to cardiovascular disorder, and the death rate is expected to grow to more than 23.6 Million by 2030. Besides, increasing healthcare expenditure has fueled the growth of the market. However, the growth of the market is restrained by the side effects of drugs for strokes and strict regulations for manufacturing medical devices for the treatment of strokes.

Transient Ischemic Attack Market Segmentation

The transient ischemic attack has been segmented into diagnosis, treatment, age group, and end user. Based on the diagnosis, the market has been divided into imaging techniques and others. The imaging technique is further sub-segmented into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance imaging, and echocardiography. The imaging technique segment accounted for a market value of USD 1004.4 Million in 2016. Based on treatment, the market has been segregated into surgery and drugs. The drugs segment is further sub-segmented into antithrombotic agents, antiplatelets, clopidogrel, aspirin, heparins, enoxaparin, dalteparin, fibrinolytic, and tenecteplase. By age groups, the market is further classified as  0–18 years, 19–40 years (Millennial), 41–60 years, and 60+ years. Based on end-user, the transient ischemic attack market has been bifurcated into hospitals & clinics, diagnostic centers, and research laboratories.

Transient Ischemic Attack Market Key Players

The prominent players in the transient ischemic attack market are: 

• Koninklijke Philips NV (Netherlands)


• Stryker Corporation (US)


• Johnson & Johnson Services Inc (US)


• Boston Scientific Corporation (US)


• Sanofi (France)


• Bayer AG (Germany)


• Pfizer Inc (US)


• Siemens AG (US)


• F. Hoffmann-La Roche AG (Switzerland)


• GE Healthcare (UK)


• Penumbra Inc (California)


• Medtronic PLC (Ireland)


• Abbott Laboratories (US)


• Merck & Co., Inc (US) 


• Boehringer Ingelheim GmbH (Germany) 

Transient Ischemic Attack Market Regional Analysis

The transient ischemic attack market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the transient ischemic attack market during the forecast period. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market. People in this region are very health conscious, which has led to increasing healthcare expenditure in this region.

Europe accounted for the second-largest market for transient ischemic attack. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region.

Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and the rising prevalence of cardiac disorders. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region. Japan held the most significant market share of 32.97 % in 2016.

The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.

Key Updates

• In February 2018, Merck & Co. Inc acquired Viralytics Limited. This acquisition expanded Merck’s immunology pipeline.

• In January 2018, Abbott entered into a definitive merger agreement by acquiring Alere Inc., a diagnostic device and service provider, for USD 56.00 per common share in cash.

• In October 2018, Stryker Corporation announced the acquisition of VEXIM, a French medical device company. This acquisition enabled Stryker Corporation to increase its revenue in the future.

• In August 2017, Sanofi completed the acquisition of Protein Sciences. This acquisition was a strategic fit for Sanofi Pasteur’s for developing new manufacturing technologies.

• In May 2017, Boston Scientific Corporation announced the acquisition of Symetis SA, to focus on minimally invasive transcatheter aortic valve implantation (TAVI) devices.

Market Segmentation

Transient Ischemic Attack Market, by Diagnosis

• Imaging Techniques


• Computed Tomography (CT) scan


• Carotid Duplex Scanning


• Magnetic Resonance Imaging


• Echocardiography            

Transient Ischemic Attack Market, by Treatment

• Surgery


• Drugs


• Antithrombotic agents


• Antiplatelets


• Clopidogrel


• Aspirin


• Heparins


• ENOXAPARIN


• DALTEPARIN


• Fibrinolytics


• Tenecteplase

Transient Ischemic Attack Market, by Age Groups

• 0–18 years


• 19–40 years (Millennial)


• 41–60 years


• 60+ years

Transient Ischemic Attack Market, by End-User

• Hospitals & Clinics


• Diagnostic Centers


• Research Laboratories

Transient Ischemic Attack Market, by Region

• Americas




• North America




• US


• Canada




• Latin America

• Europe




• Western Europe




• Germany


• UK


• France


• Italy


• Spain


• Rest of Western Europe




• Eastern Europe

• Asia-Pacific




• China


• Japan


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• Africa

Available Additional Customizations

• Additional Companies




• LivaNova PLC


• EnteroMedics Inc.


• ElectroCore Medical LLC


• Cyberonics, Inc.


• NeuroMetrix, Inc.


• ImThera Medical


• Inspire Medical Systems, Inc.


• Nihon Kohden Corporation


• Electrical Geodesics Inc.

Intended Audience

• Medical device manufacturers and distributors


• Government research organizations


• Hospitals and clinics


• Regulatory agencies


• Contract research organizations


• Academic institutes and universities